Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IVD Firms Need To Plan Ahead For EU IVD Directive, Consultant Advises

This article was originally published in The Gray Sheet

Executive Summary

Manufacturers should begin preparations for the April 2000 implementation of the European Union In Vitro Diagnostics Directive, Maurizio Suppo, principal consultant for Belgium-based MTC advised at an Oct. 28 Regulatory Affairs Professional Society meeting in Washington, D.C.

You may also be interested in...



Underwriters Laboratory Joins Growing List of Notified Bodies For IVDD

Underwriters Laboratory (UL) plans to expand its notified body (NB) certification status to include the full scope of in vitro diagnostic products by early 2001.

Could Eledon’s Anti-CD40L Change Transplant Medicine?

Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation. 

Latest Headlines
See All
UsernamePublicRestriction

Register

MT010848

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel